跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 93 条关于
“Inventera”
全部
93
临床试验
65
药物
2
机构
5
资讯
21
15小时前
Inventera's Gadolinium-Free MRI Contrast Agent INV-002 Hits All Phase 3 Endpoints in MR Arthrography
3个月前
Four ASBMB Members Named 2025 National Academy of Inventors Fellows
去年
Inventiva Secures €21.4 Million to Advance Lanifibranor in MASH Phase III Trial
去年
Inventiva Restructures: Halves Workforce to Focus on Late-Stage MASH Drug Lanifibranor
去年
Inventiva Secures €348 Million to Advance Phase 3 MASH Study of Lanifibranor
去年
Inventiva Files 2024 Half-Year Report, Advancing Lanifibranor for MASH/NASH Treatment
去年
Inventiva Secures €348 Million to Advance Lanifibranor Phase III Trial for MASH
去年
Lanifibranor Plus Empagliflozin Shows Promise in MASH and Type 2 Diabetes
去年
Inventiva Slashes Workforce and Programs to Focus on Late-Stage MASH Drug Lanifibranor
去年
Inventiva Receives $10 Million Milestone Payment from CTTQ for MASH Drug Development Partnership
第 1 页,共 3 页
上一页
下一页